# Chengyi Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chengyi-biotechnology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.eccogene.com
- Total disclosed funding: $55M
- Latest round: Series B (Jun 12, 2023)
- Investors on record: 13

## About

Based in Shanghai, China and established in 2018, Chengyi Biotechnology is a pharmaceutical company that focuses on developing innovative small-molecule drugs. Jingye Zhou, the founder and CEO of the company, used to be the head of the chemical department of Lilly China R&D Center. In June 2023, the company raised CNY 180 million in series B funding co-led by new investors New Alliance Capital and Zhangjiang Venture. Other returning investors Delos Capital Partners, Oriza Holdings, Tsing Song Capital, new investors Elikon Venture, Golden China Fund, Rockbleu Capital, and Yufu Investment also participated in the round.

The company's main products include low-dose small molecule GLP-1 receptor agonists, THR-ß full agonists and SSAO/VAP-1 inhibitors, etc. Its products are used in metabolic and immune-related diseases.

The company will use the series B funding for phase I clinical trials of small molecule GLP-1 receptor agonist ECC5004 for obesity and type 2 diabetes, and phase I clinical trials of THR-ß full agonist ECC4703 for NASH and lipid disorders.

## Funding rounds

- Series B, Jun 12, 2023, $25M — Oriza Holdings, Golden China Fund, Shanghai Zhangjiang Science & Technology Venture Capital, New Alliance Capital, Delos Capital Partners, Tsing Song Capital, Elikon Venture, Rockbleu Capital, Yufu Investment
- Series C, Mar 16, 2021 — Shanghai Jianyi Private Equity Fund Management, Huagai Capital, Delos Capital Partners, Tsing Song Capital, Oriza Holdings
- Series A, Dec 22, 2020, $15M — Oriza Holdings, Shanghai Jianyi Private Equity Fund Management, Huagai Capital, Delos Capital Partners, Tsing Song Capital
- Series A, Sep 6, 2018, $15M — Shanghai Jianyi Private Equity Fund Management, MED-FINE Capital, TF Capital

## Investors

- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series A, Series C
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A
- TF Capital — Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A, Series C, Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A, Series C
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series A, Series C, Series B
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A, Series C, Series B
- Golden China Fund (https://capitalatlas.ai/funds/golden-china-fund) — Series B
- Shanghai Zhangjiang Science & Technology Venture Capital — Series B
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series B
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series B
- Rockbleu Capital — Series B
- Yufu Investment — Series B